HCPCS Level II code J2430 denotes a 30 mg unit of pamidronate disodium administered by injection. Nationally, this billing code is relevant for oncology and metabolic bone disease care, where intravenous bisphosphonate therapy is used to manage malignancy-associated bone complications and hypercalcemia. Proper unitization and site-of-service designation affect claim adjudication and aggregate spending for outpatient infusion therapy.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for utilization and unit pricing, guidance on typical sites of service and service-line classification, and a clinical context that links J2430 use to oncology and specialty infusion care. The publication highlights common billing considerations and payor coverage patterns without offering provider recommendations.

This summary equips billing managers, revenue cycle professionals, and policy analysts with a concise reference to how J2430 is used in outpatient infusion settings, what to expect from major payers nationally, and which clinical situations typically drive use of pamidronate disodium.